强生 2024年度报告

Johnson&Johnson Our Credo We believe our first responsibility is to the patients, doctors and nurses,to mothers and fathers and all others who use our products andservices. In meeting their needs everything we do must be of highquality. We must constantly strive to provide value, reduce our costsand maintain reasonable prices. Customers' orders must be servicedpromptly and accurately. Our business partners must have anopportunity to make a fair profit.                                              We are responsible to our employees who work with us throughout theworld. We must provide an inclusive work environment where eachperson must be considered as an individual. We must respect theirdiversity and dignity and recognize their merit. They must have a senseof security, fulfillment and purpose in their jobs. Compensation must befair and adequate and working conditions clean, orderly and safe. Wemust support the health and well-being of our employees and help themfulfill their family and other personal responsibilities. Employees mustfeel free to make suggestions and complaints. There must be equalopportunity for employment, development and advancement for thosequalified. We must provide highly capable leaders and their actions mustbe just and ethical.                    !  "     #             $            %         "          # We are responsible to the communities in which we live and work and tothe world community as well. We must help people be healthier bysupporting better access and care in more places around the world. Wemust be good citizens — support good works and charities, betterhealth and education, and bear our fair share of taxes. We mustmaintain in good order the property we are privileged to use, protectingthe environment and natural resources.                  ! &          '         Our final responsibility is to our stockholders. Business must make asound profit. We must experiment with new ideas. Research must becarried on, innovative programs developed, investments made for thefuture and mistakes paid for. New equipment must be purchased, newfacilities provided and new products launched. Reserves must becreated to provide for adverse times. When we operate according tothese principles, the stockholders should realize a fair return.           ( '  )            *      )                  !    Johnson&Johnson Dear shareholders,   Innovative Medicine     In 2024, we continued to establish Johnson & Johnson ashealthcare's leading, most comprehensive innovationpowerhouse.+,+-     . /.            Innovative Medicine reported $57 billion in sales.DARZALEX became our first brand to exceed $3 billion insales in a single quarter and SPRAVATO became our 26thplatform to generate at least $1billion in annual revenue.Other key growth drivers include ERLEADA, CARVYKTI,and TREMFYA. < 4:1   @5)A5B%C   '4D      9=)5;5"+8   43        %)B%5@55);EF"")%<0E5 With our focus on pharmaceuticals and medicaltechnology, we stand alone in our ability to impact the fullspectrum of disease.